[닫기]
잠시만 기다려 주세요. 로딩중입니다.

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma

Cancer Research and Treatment 2019년 51권 4호 p.1578 ~ 1588
 ( Lee Jii-Bum ) - Yonsei University College of Medicine Yonsei Cancer Center Department of Internal Medicine

 ( Park Hyung-Soon ) - Catholic University College of Medicine St. Vincent’s Hospital Department of Internal Medicine
 ( Park Se-Jung ) - Yonsei University College of Medicine Department of Biostatistics
 ( Lee Hyo-Jin ) - Chungnam National University College of Medicine Department of Internal Medicine
 ( Kwon Kyung-A ) - Dongnam Institute of Radiological and Medical Sciences Department of Internal Medicine Division of Hematology-Oncology
 ( Choi Young-Jin ) - Pusan National University School of Medicine Department of Internal Medicine
 ( Kim Yu-Jung ) - Seoul National University Bundang Hospital Department of Internal Medicine
 ( Nam Chung-Mo ) - Yonsei University College of Medicine Department of Preventive Medicine
 ( Cho Nam-Hoon ) - Yonsei University College of Medicine Department of Pathology
 ( Kang Beo-Deul ) - Yonsei University College of Medicine Yonsei Cancer Center Division of Medical Oncology
 ( Chung Hyun-Cheol ) - Yonsei University College of Medicine Yonsei Cancer Center Department of Internal Medicine
 ( Rha Sun-Young ) - Yonsei University College of Medicine Yonsei Cancer Center Department of Internal Medicine

Abstract


Purpose: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naive Asian patients with metastatic/recurrent nccRCC.

Materials and Methods: From January 2008 to July 2017, data of treatment-naive, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus.

Results: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]).

Conclusion: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.

키워드

Temsirolimus; First-line; Asian; Renal cell carcinoma; Efficacy; Tolerability
원문 및 링크아웃 정보
  
등재저널 정보
SCI(E)
MEDLINE
KCI
KoreaMed
KAMS